Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a phone app lift depression? new trial puts digital therapy to the test

NCT ID NCT05554289

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a smartphone app called WL-iCBT that delivers cognitive behavioral therapy through videos, exercises, and interactive tools. 315 adults with mild-to-moderate depression used either the active app or a placebo version for 8 weeks. Researchers measured changes in depression severity, anxiety, and daily functioning to see if the app helps ease symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
smartphone app delivering cognitive behavioral therapy and attention bias modification
What this could lead to
If it works, this could provide a convenient, accessible treatment option for mild-to-moderate depression that people can use at home.
What could go wrong
This is a completed trial, but results are not yet published. The app may not outperform a placebo, and benefits may vary by individual. Digital therapies also require user engagement to be effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

315 people

The number who actually took part.

Started

Apr 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntary participation in the trial with signed informed consent 2. Age 18-60 years (inclusive), any gender 3. Clinical diagnosis of Major Depressive Disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria, confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.7.0.2), with either single episode or recurrent episodes without psychotic features 4. Montgomery-Asberg Depression Rating Scale (MADRS) score ≥18 and \<30 at screening 5. No antidepressant medication within 2 weeks prior to screening (6 weeks for fluoxetine), and assessed by the investigator as able to maintain without antidepressant medication during the trial period 6. Education level of primary school or above, able to understand the content of assessment scales, and proficient in using smartphones Exclusion Criteria: 1. Current clinical diagnosis meeting DSM-5 criteria for psychiatric disorders other than Major Depressive Disorder (confirmed by M.I.N.I.7.0.2) 2. Treatment-resistant depression (defined as patients who failed to respond to adequate doses and duration (at least 4 weeks at maximum recommended dose) of 2 or more antidepressants with different chemical structures) 3. History of alcohol and drug dependence 4. Pregnant or lactating women, or men or women planning pregnancy during the clinical trial period 5. Current serious physical disease, thyroid disease (thyroid stimulating hormone (TSH) exceeding the upper limit of normal at screening), or patients considered by investigators to have hypothyroidism or hyperthyroidism (at the investigator's discretion, laboratory tests meeting exclusion criteria may be rechecked once within the screening period) 6. Obvious suicidal attempt or behavior, with a score ≥4 on item 10 "Suicidal Thoughts" of the MADRS scale 7. Patients who have received other antidepressant treatments within 3 months prior to enrollment, including Chinese herbal medicine, modified electroconvulsive therapy, transcranial magnetic stimulation, biofeedback therapy, light therapy, acupuncture, and other physical or systematic psychological treatments 8. Patients who explicitly express unwillingness to participate in psychological therapy or believe psychological therapy is ineffective 9. Patients who have participated in or are currently participating in drug clinical trials within 3 months prior to screening, or in other device clinical trials within 1 month prior to screening 10. Other conditions deemed unsuitable for enrollment by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chengdu Fourth People's Hospital (Chengdu Mental Health Center)

    Chengdu, Sichuan, China

  • Ningbo Kangning Hospital

    Ningbo, Zhejiang, China

  • Quzhou Third Hospital

    Quzhou, Zhejiang, China

  • Shenzhen Kangning Hospital

    Shenzhen, Guangdong, China

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Zhuhai, Guangdong, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunan, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shannxi, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Zhejiang Provincial Tongde Hospital

    Hangzhou, Zhejiang, China

  • Zhumadian Second People's Hospital

    Zhumadian, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.